HC Wainwright Reaffirms Buy Rating for Plus Therapeutics (NASDAQ:PSTV)

Plus Therapeutics (NASDAQ:PSTV)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $8.00 price objective on the stock.

Separately, Ascendiant Capital Markets dropped their target price on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd.

Plus Therapeutics Trading Down 1.6 %

PSTV opened at $1.26 on Tuesday. Plus Therapeutics has a twelve month low of $1.12 and a twelve month high of $2.67. The firm has a market cap of $7.43 million, a price-to-earnings ratio of -0.50 and a beta of 0.69. The company has a fifty day simple moving average of $1.36 and a 200 day simple moving average of $1.62.

Institutional Investors Weigh In On Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC acquired a new stake in Plus Therapeutics, Inc. (NASDAQ:PSTV) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned 9.98% of Plus Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.